Introduction {#H1-1-ZOI190121}
============

The global epidemic of diabetes has rapidly spread to every country in Asia.^[@zoi190121r1]^ Currently, more than 230 million Asian individuals are living with diabetes, accounting for approximately 55% of the world's diabetic population, and this number is expected to exceed 355 million by 2040.^[@zoi190121r2]^ Two Asian countries, China and India, are home to the largest number of patients with diabetes in the world (110 million and 69.2 million, respectively).^[@zoi190121r2]^ Three other Asian countries, Indonesia, Japan, and Bangladesh, are also ranked among the countries with the highest number of patients with diabetes worldwide.^[@zoi190121r1],[@zoi190121r2]^ Given the increasing prevalence of obesity and the rapid adoption of a Westernized lifestyle in most Asian countries (especially developing countries),^[@zoi190121r3],[@zoi190121r4]^ the diabetes epidemic will likely continue to impose a burden on public health systems across Asia.^[@zoi190121r1],[@zoi190121r3],[@zoi190121r5]^

Emerging evidence suggests that diabetes in Asia shows unique features: compared with their Western counterparts, Asian individuals develop diabetes at a younger age and at a lower body mass index (BMI) and have a greater risk of developing complications, which may cause premature death.^[@zoi190121r1],[@zoi190121r5]^ In addition, there are differences in genetics, socioeconomic factors, and diabetes management approaches between Asia and other continents, which may lead to a varied influence of diabetes on mortality in Asia.^[@zoi190121r1],[@zoi190121r6],[@zoi190121r7]^ However, limited studies have prospectively quantified the association of diabetes with all-cause and cause-specific mortality in Asian populations and/or have examined potential effect modifiers on the association. In this pooled analysis of 22 prospective cohort studies, we assessed the association of diabetes with all-cause and cause-specific mortality in more than 1 million Asian individuals from multiple countries and regions and further investigated potential effect modifications of diabetes-mortality associations by participants' age, sex, education level, BMI, and smoking status.

Methods {#H1-2-ZOI190121}
=======

Study Populations {#H2-1-ZOI190121}
-----------------

This study includes 22 prospective cohort studies in multiple countries and regions---mainland China, Japan, South Korea, Singapore, Taiwan, India, and Bangladesh---participating in the Asia Cohort Consortium (ACC). Details of the ACC have been described elsewhere.^[@zoi190121r8]^ Brief descriptions of participating cohorts are given in the eAppendix in the [Supplement](#note-ZOI190121-1-s){ref-type="supplementary-material"}. All cohort studies and the current pooled analysis received approval from the ethics committees of the host institutions. All study participants provided informed consent to the parent cohort studies. Each cohort collected baseline and outcome data according to its study protocol. The ACC coordinating center obtained deidentified individual participant data from each cohort and harmonized it across cohorts. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

Exposure and Outcome Assessment {#H2-2-ZOI190121}
-------------------------------

Data on self-reported doctor-diagnosed diabetes were collected at baseline in all participating cohorts and used in the previous ACC pooled analyses.^[@zoi190121r8],[@zoi190121r9],[@zoi190121r10]^ The overall validity of self-reported diabetes was evaluated in several participating cohorts, showing a very high specificity (approximately 99%) and a moderate sensitivity (approximately 62%).^[@zoi190121r9],[@zoi190121r10],[@zoi190121r11],[@zoi190121r12],[@zoi190121r13]^ Information on types of diabetes was unavailable in the ACC; however, among one-third of patients with diabetes who reported their age at the first diagnosis, only 0.2% were diagnosed before the age of 20 years, which was consistent with a low prevalence of type 1 diabetes in Asia.^[@zoi190121r14]^ Additionally, we excluded participants younger than 30 years at enrollment. Thus, nearly all patients with diabetes were diagnosed with type 2 diabetes. No clinical information, such as glucose levels and use of medications, was collected in most of the participating cohorts.

For mortality information, all study participants were followed up through data linkages to death certificates and/or active follow-up surveys. According to the *International Classification of Diseases, Ninth Revision* or *International Classification of Diseases, Tenth Revision,* the primary cause of death was coded for cause-specific mortality (eTable 1 in the [Supplement](#note-ZOI190121-1-s){ref-type="supplementary-material"}). The Ibaraki Prefectural Health Study (Japan) ascertained the date of death without underlying causes; hence, it was only included in the analysis of all-cause mortality.

Statistical Analysis {#H2-3-ZOI190121}
--------------------

Of the 1 154 333 individuals included in these cohorts, we excluded 94 460 with unknown status on diabetes at baseline and 7889 with missing or incorrect information concerning vital status, duration of follow-up, or age at baseline (\<30 years). To minimize the potential influence of underlying diseases other than diabetes on mortality risk, we further excluded data from the first 3 years of follow-up, including 49 433 participants who were followed up for less than 3 years. After these exclusions, 1 002 551 participants (484 014 men and 518 537 women) remained for the current analysis ([Table 1](#zoi190121t1){ref-type="table"}).

###### Characteristics of Participating Cohorts in the Asia Cohort Consortium

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort                                                            Participants, No.[^a^](#zoi190121t1n1){ref-type="table-fn"}   Baseline\      Follow-up, Median (Range), y[^b^](#zoi190121t1n2){ref-type="table-fn"}   Women, No. (%)   Age at Baseline, Median (Range), y   Diabetes, No. (%)   Deaths, No.    
                                                                                                                                  Survey Dates                                                                                                                                                                     
  ----------------------------------------------------------------- ------------------------------------------------------------- -------------- ------------------------------------------------------------------------ ---------------- ------------------------------------ ------------------- -------------- ---------
  Mainland China                                                                                                                                                                                                                                                                                                   

  China National Hypertension Survey Epidemiology Follow-up Study   138 640                                                       1990-1992      8.2 (3.0-9.9)                                                            70 737 (51.0)    54.0 (40.0-91.0)                     1400 (2.1)          1515 (2.1)     12 453

  Shanghai Cohort Study                                             17 703                                                        1986-1989      18.0 (3.0-21.1)                                                          NA               55.0 (35.0-76.0)                     222 (1.3)           NA             4607

  Shanghai Men's Health Study                                       60 379                                                        2001-2006      9.7 (3.0-13.4)                                                           NA               52.0 (40.0-75.0)                     3692 (6.1)          NA             4346

  Shanghai Women's Health Study                                     74 188                                                        1996-2000      15.3 (3.0-18.4)                                                          74 188 (100.0)   50.0 (40.0-70.0)                     NA                  3172 (4.3)     6903

  Linxian General Population Trial Cohort                           28 532                                                        1984-1987      23.2 (3.0-25.8)                                                          15 929 (55.8)    51.0 (30.0-81.0)                     18 (0.1)            13 (0.1)       15 320

  Japan                                                                                                                                                                                                                                                                                                            

  3 Prefecture Aichi Study                                          20 529                                                        1985-1985      15.2 (3.0-15.5)                                                          11 048 (53.8)    53.0 (40.0-97.0)                     554 (5.8)           368 (3.3)      2867

  Ibaraki Prefectural Health Study                                  95 537                                                        1993-1994      12.3 (3.0-12.7)                                                          63 222 (66.2)    60.0 (39.0-79.0)                     1255 (3.9)          1416 (2.2)     9721

  Japan Collaborative Cohort Study                                  73 351                                                        1988-1990      14.3 (3.0-16.0)                                                          42 820 (58.4)    57.0 (40.0-79.0)                     2060 (6.8)          1833 (4.3)     9387

  Japan Public Health Center-Based prospective Study 1              42 548                                                        1990-1992      22.6 (3.0-23.0)                                                          22 255 (52.3)    50.0 (40.0-59.0)                     1114 (5.5)          555 (2.5)      7069

  Japan Public Health Center-Based Prospective Study 2              55 530                                                        1992-1995      19.7 (3.0-20.0)                                                          29 415 (53.0)    55.0 (40.0-69.0)                     1980 (7.6)          1096 (3.7)     11 964

  3 Prefecture Miyagi Study                                         27 954                                                        1984-1984      15.0 (3.0-15.0)                                                          15 679 (56.1)    56.0 (40.0-98.0)                     879 (7.2)           648 (4.1)      5436

  Miyagi Cohort                                                     46 543                                                        1990-1990      17.8 (3.0-17.8)                                                          24 311 (52.2)    53.0 (40.0-64.0)                     1182 (5.3)          771 (3.2)      5340

  Ohsaki National Health Insurance Cohort Study                     45 217                                                        1994-1994      13.2 (3.0-13.2)                                                          23 561 (52.1)    62.0 (40.0-80.0)                     1568 (7.2)          1357 (5.8)     8141

  Life Span Study                                                   39 314                                                        1963-1993      21.9 (3.0-38.9)                                                          20 994 (53.4)    51.0 (30.0-97.0)                     1681 (9.2)          1181 (5.6)     20 073

  Takayama Study                                                    25 694                                                        1992-1992      15.6 (3.0-15.6)                                                          14 217 (55.3)    54.0 (35.0-97.0)                     840 (7.3)           471 (3.3)      4810

  Korea                                                                                                                                                                                                                                                                                                            

  Korean Multi-center Cancer Cohort Study                           12 607                                                        1993-2004      14.4 (3.0-20.5)                                                          7665 (60.8)      56.0 (30.0-89.0)                     222 (4.5)           360 (4.7)      2260

  Seoul Male Cancer Cohort                                          13 767                                                        1992-1993      16.0 (3.1-16.0)                                                          NA               49.0 (31.0-82.0)                     423 (3.1)           NA             836

  Singapore                                                                                                                                                                                                                                                                                                        

  Singapore Chinese Health Study                                    61 298                                                        1993-1999      12.5 (3.0-14.9)                                                          34 494 (56.3)    55.0 (43.0-83.0)                     2161 (8.1)          3041 (8.8)     8733

  Taiwan                                                                                                                                                                                                                                                                                                           

  Community-Based Cancer Screening Project                          23 425                                                        1991-1992      15.9 (3.0-16.9)                                                          11 703 (50.0)    47.0 (30.0-66.0)                     318 (2.7)           251 (2.1)      2452

  Cardiovascular Disease Risk Factor Two-Township Study             4264                                                          1990-1993      15.7 (3.0-17.2)                                                          2381 (55.8)      51.0 (30.0-91.0)                     71 (3.8)            100 (4.2)      741

  Bangladesh                                                                                                                                                                                                                                                                                                       

  Health Effects for Arsenic Longitudinal Study                     8489                                                          2000-2002      12.7 (3.0-13.5)                                                          4185 (49.3)      40.0 (30.0-75.0)                     132 (3.1)           121 (2.9)      677

  India                                                                                                                                                                                                                                                                                                            

  Mumbai Cohort Study                                               87 042                                                        1991-1997      5.7 (3.0-8.1)                                                            29 733 (34.2)    50.0 (35.0-98.0)                     1511 (2.6)          385 (1.3)      4732

  Total                                                             1 002 551                                                     1963-2006      12.6 (3.0-38.9)                                                          518 537 (51.7)   54.0 (30.0-98.0)                     23 283 (4.8)        18 654 (3.6)   148 868
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: NA, not available.

Includes only participants who were eligible for the current pooled analysis.

Median years of total follow-up time interval from study entry to the final date of last contact (end of follow-up, date of death, or loss to follow-up).

A 2-stage individual participant data meta-analysis was applied.^[@zoi190121r15]^ First, we evaluated the associations between diabetes and mortality in each cohort separately. Then, cohort-specific hazard ratios (HRs) and 95% confidence intervals were pooled using the random-effects meta-analysis method.^[@zoi190121r16]^ Proportionality assumption was tested using the global goodness-of-fit test with Schoenfeld residuals in each cohort---there was no evidence of a violation. In the Cox models, age was treated as the time scale, using age at enrollment (entry) and age at the final follow-up (exit), which was either the date of death or the date of last contact (ie, end of follow-up or loss to follow-up), whichever came first. All Cox models were stratified by 5-year intervals of birth year and enrollment year to account for the difference in calendar time across study populations. Covariates included age at baseline (continuous), smoking status (current, former, and never), smoking pack-year (0, 0.1-20.0, 20.1-40.0, and \>40.0 pack-years), educational attainment (no formal schooling, primary education, secondary education, college education, university graduate, and postgraduate), marital status (single, married, and other), residential area (urban and rural), and BMI (\<18.50, 18.50-24.99, 25.00-29.99, and ≥30.00; calculated as weight in kilograms divided by height in meters squared). The proportion of missing covariates was less than 10% in most participating cohorts. Missing covariates were imputed using the median (for continuous variables) or mode (for categorical variables) values of cohort-specific nonmissing covariates. In the sensitivity analyses, we excluded participants who had a history of cardiovascular disease (CVD) or cancer (except for nonmelanoma skin cancer) at baseline. Furthermore, we excluded 1 country at a time from the meta-analysis to assess the robustness of the overall findings.

To estimate the overall risk of death associated with diabetes among Asian populations, we first compared cause-specific death rates between individuals with and without diabetes. Death rates by diabetes status were estimated with age- and sex-specific deaths and person-years at risk, which were standardized according to the age and sex distribution of the ACC populations. The diabetes-mortality association, measured using HRs and 95% CIs, was evaluated for all participants and by sex (men and women), age at baseline (30-49, 50-59, 60-69, and ≥70 years), educational attainment (less than primary school graduation, secondary school, trade or technical school, and university graduation or greater), BMI (\<18.50, 18.50-22.99, 23.00-24.99, and ≥25.00), and smoking status (never, former, and current). The interaction between diabetes and individual characteristics was tested by a 2-stage method^[@zoi190121r17]^: the interactions were estimated in each cohort by using the likelihood ratio test entering a cross-product term of diabetes and the stratification variable. Then, the cohort-specific estimates (regression coefficients and variances) were pooled using random-effects meta-analysis. A 2-sided *P* value of less than .05 was considered statistically significant. All statistical procedures were conducted using SAS statistical software version 9.3 (SAS Institute Inc).

Results {#H1-3-ZOI190121}
=======

During a median (range) follow-up of 12.6 (3.0-38.9) years, 148 868 deaths were ascertained among 1 002 551 participants (518 537 \[51.7%\] female; median \[range\] age, 54.0 \[30.0-98.0\] years). The overall prevalence of self-reported diabetes was 4.8% for men and 3.6% for women ([Table 1](#zoi190121t1){ref-type="table"}).

Diabetes was associated with a 1.89-fold increase in risk of death from all causes (HR, 1.89; 95% CI, 1.74-2.04) ([Table 2](#zoi190121t2){ref-type="table"}). Specifically, patients with diabetes were at an increased risk of death from a wide range of diseases, with the highest relative risk for death due to diabetes itself (HR, 22.8; 95% CI, 18.5-28.1); followed by renal disease (HR, 3.08; 95% CI 2.50-3.78), including kidney failure (HR, 3.32; 95% CI, 2.67-4.12) and other renal disease (HR, 2.72; 95% CI, 1.98-3.74); coronary heart disease (HR, 2.57; 95% CI, 2.19-3.02); tuberculosis (HR, 2.28; 95% CI, 1.41-3.69); liver disorder (HR, 2.24; 95% CI, 1.87-2.68); and ischemic stroke (HR, 2.15; 95% CI, 1.85-2.51). Significant positive associations with diabetes were also found for risk of death from hemorrhagic stroke, digestive system disease, certain cancers (eg, liver, breast, pancreas, gallbladder, and colon or rectum), infectious disease, and mental disorder. However, a significant inverse association was found between diabetes and death from chronic obstructive pulmonary disease.

###### All-Cause and Cause-Specific Mortality Associated With Diabetes in Asian Populations

  Cause                                                                  Diabetes   No Diabetes   Adjusted HR (95% CI)[^b^](#zoi190121t2n2){ref-type="table-fn"}           
  ---------------------------------------------------------------------- ---------- ------------- ---------------------------------------------------------------- ------- ------------------
  All causes                                                             12 465     166           136 403                                                          126.4   1.89 (1.74-2.04)
  Cardiovascular disease                                                                                                                                                   
  Coronary heart disease                                                 1471       17.4          9107                                                             6.8     2.57 (2.19-3.02)
  Stroke, all types                                                      1582       20.4          16 235                                                           17.1    1.81 (1.61-2.04)
  Ischemic stroke                                                        576        7.4           4815                                                             7.4     2.15 (1.85-2.51)
  Hemorrhage stroke                                                      470        7.4           6433                                                             5       1.38 (1.17-1.62)
  Other                                                                  1094       15.7          12 181                                                           16.5    1.73 (1.53-1.96)
  Endocrine, nutritional, and metabolic disease                                                                                                                            
  Diabetes                                                               1456       17.1          1165                                                             0.6     22.8 (18.5-28.1)
  Other                                                                  31         1.2           681                                                              0.6     1.68 (1.08-2.61)
  Cancer                                                                                                                                                                   
  Lung                                                                   501        5.2           8380                                                             4.8     0.98 (0.89-1.07)
  Breast                                                                 76         0.9           1071                                                             0.9     1.74 (1.28-2.38)
  Colorectal                                                             359        3.3           4274                                                             2.9     1.30 (1.16-1.46)
  Stomach                                                                394        4.8           6880                                                             4.2     1.10 (0.96-1.25)
  Liver                                                                  459        4.9           4067                                                             2.5     1.89 (1.59-2.24)
  Pancreas                                                               224        2.6           2393                                                             1.3     1.55 (1.31-1.84)
  Gallbladder                                                            136        1.4           1628                                                             1       1.38 (1.16-1.65)
  Female reproductive organs[^c^](#zoi190121t2n3){ref-type="table-fn"}   67         0.9           1160                                                             0.7     1.21 (0.93-1.56)
  Other                                                                  723        8.7           10 430                                                           7.4     1.22 (1.13-1.32)
  Renal disease                                                                                                                                                            
  Kidney failure                                                         232        2.7           1211                                                             1.5     3.32 (2.67-4.12)
  Other                                                                  181        2.6           1104                                                             0.8     2.72 (1.98-3.74)
  Digestive system disease                                                                                                                                                 
  Liver disorder[^d^](#zoi190121t2n4){ref-type="table-fn"}               227        3.7           2234                                                             1.8     2.24 (1.87-2.68)
  Gallbladder, biliary tract, and pancreas                               45         0.5           452                                                              2.8     2.04 (1.48-2.80)
  Stomach, esophagus, and duodenum                                       34         0.3           402                                                              0.5     1.73 (1.20-2.49)
  Other                                                                  131        1.3           1208                                                             1.1     2.10 (1.63-2.70)
  Respiratory disease                                                                                                                                                      
  Pneumonia                                                              790        18.8          6595                                                             11.9    1.79 (1.51-2.11)
  Asthma                                                                 27         0.3           581                                                              0.6     1.20 (0.81-1.79)
  Chronic obstructive pulmonary disease                                  100        0.7           2549                                                             1.8     0.78 (0.63-0.96)
  Other                                                                  232        2.2           2,336                                                            2.8     1.59 (1.38-1.82)
  Infectious disease                                                                                                                                                       
  Tuberculosis                                                           38         0.5           802                                                              0.9     2.28 (1.41-3.69)
  Other                                                                  162        8.5           1701                                                             1.1     2.00 (1.62-2.47)
  Other known disease                                                                                                                                                      
  Mental disorder                                                        32         0.4           542                                                              0.7     1.93 (1.22-3.05)
  Nervous system disorder                                                63         0.6           1193                                                             1       1.10 (0.84-1.45)
  Other                                                                  697        10.4          10 060                                                           16.5    1.42 (1.23-1.64)
  Not specified[^e^](#zoi190121t2n5){ref-type="table-fn"}                901        7.8           23 781                                                           13      1.73 (1.61-1.85)

Abbreviation: HR, hazard ratio.

Death rate per 1000 person-years, standardized by age and sex.

Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

Malignant neoplasms of vagina, cervix uteri, corpus uteri, uterus, ovary, vulva, and other female genital organs.

Liver cirrhosis, hepatic failure, chronic hepatitis, fibrosis, alcoholic or toxic liver disease, and other kinds of liver disorders.

Unknown causes including missing and invalid data on cause of death.

We found some differences in the diabetes-mortality association by country and region: the relative risks were greater than 2.6-fold in Taiwan and rural China; approximately 2.2-fold in Bangladesh, Singapore, and urban China; and less than 2.0-fold in Japan, South Korea, and India (*P* for heterogeneity \<.001) (eFigure in the [Supplement](#note-ZOI190121-1-s){ref-type="supplementary-material"}). Furthermore, the magnitude of the diabetes-mortality association differed by sex, age, and smoking status among women ([Table 3](#zoi190121t3){ref-type="table"}). The relative risk for all-cause mortality was greater among women (HR, 2.09; 95% CI, 1.89-2.32) than among men (HR, 1.74; 95% CI, 1.62-1.88) (*P* for interaction \< .001) and greater among participants aged 30 to 49 years (HR, 2.43; 95% CI, 2.08-2.84) than for those aged 50 to 59 years (HR, 2.06; 95% CI, 1.83-2.31), 60 to 69 years (HR, 1.87; 95% CI, 1.71-2.05), and 70 years or older (HR, 1.51; 95% CI, 1.40-1.62) (*P* for interaction \<.001). Among women only, the diabetes-mortality association was stronger among those who had never smoked than among current smokers (HR, 2.13; 95% CI, 1.93-2.36 vs HR, 1.81; 95% CI, 1.59-2.06, respectively) (*P* for interaction = .009). No significant differences were found by smoking status among men, educational attainment, or BMI levels.

###### All-Cause Mortality Associated With Diabetes Stratified by Individual Characteristics in Asian Populations

  Characteristic                                                     No.      Adjusted HR (95% CI)[^a^](#zoi190121t3n1){ref-type="table-fn"}   *P* Value for Interaction                               
  ------------------------------------------------------------------ -------- ---------------------------------------------------------------- --------------------------- -------- ------------------ --------
  Sex                                                                                                                                                                                                  
  Men                                                                23 283   7231                                                             460 731                     79 405   1.74 (1.62-1.88)   \<.001
  Women                                                              18 654   5234                                                             499 883                     56 998   2.09 (1.89-2.32)   
  Age at baseline, y                                                                                                                                                                                   
  \<50                                                               7386     1106                                                             359 919                     19 086   2.43 (2.08-2.84)   \<.001
  50-59                                                              13 742   3131                                                             303 771                     37 104   2.06 (1.83-2.31)   
  60-69                                                              15 262   5372                                                             222 688                     51 069   1.87 (1.71-2.05)   
  ≥70                                                                5547     2856                                                             74 236                      29 144   1.51 (1.40-1.62)   
  Educational attainment[^b^](#zoi190121t3n2){ref-type="table-fn"}                                                                                                                                     
  ≤Primary school                                                    15 392   5410                                                             326 333                     65 069   1.98 (1.74-2.24)   .72
  Secondary school                                                   10 584   2820                                                             228 826                     27 315   1.94 (1.74-2.17)   
  Trade or technical school                                          3814     764                                                              99 961                      6687     1.79 (1.65-1.95)   
  ≥University graduation                                             3369     655                                                              102 115                     7900     1.69 (1.47-1.94)   
  Body mass index[^c^](#zoi190121t3n3){ref-type="table-fn"}                                                                                                                                            
  \<18.5                                                             1500     687                                                              69 637                      14 564   1.87 (1.62-2.15)   .24
  18.5-22.9                                                          14 813   4847                                                             427 259                     64 845   1.96 (1.77-2.16)   
  23.0-24.9                                                          10 913   3127                                                             224 093                     28 238   1.86 (1.69-2.04)   
  ≥25.0                                                              14 711   3804                                                             239 625                     28 756   1.85 (1.69-2.02)   
  Smoking status for men                                                                                                                                                                               
  Never                                                              6799     1593                                                             151 267                     18 616   1.84 (1.64-2.08)   .14
  Former                                                             5237     1778                                                             67 465                      13 317   1.62 (1.51-1.75)   
  Current                                                            11 247   3860                                                             241 999                     47 472   1.70 (1.58-1.83)   
  Smoking status for women                                                                                                                                                                             
  Never                                                              16 749   4514                                                             462 968                     50 414   2.13 (1.93-2.36)   .009
  Former                                                             451      177                                                              5652                        1095     1.98 (1.55-2.52)   
  Current                                                            1454     543                                                              31 263                      5489     1.81 (1.59-2.06)   

Abbreviation: HR, hazard ratio.

Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

Cohorts (3 Prefecture Aichi Study, 3 Prefecture Miyagi Study, Ibaraki Prefectural Health Study, Japan Public Health Center-Based Prospective Study 2, Korean Multi-center Cancer Cohort Study) without information on education were not included in the analysis.

Calculated as weight in kilograms divided by height in meters squared.

Potential modifying effects of sex, age, and BMI on the associations of diabetes with cause-specific mortality in Asian populations are shown in [Table 4](#zoi190121t4){ref-type="table"} and [Table 5](#zoi190121t5){ref-type="table"} and eTable 2 in the [Supplement](#note-ZOI190121-1-s){ref-type="supplementary-material"}. Multiple CVD mortality outcomes (ie, total CVD, coronary heart disease, and ischemic stroke) and renal disease mortality showed stronger associations with diabetes among women than among men. Meanwhile, many mortality outcomes, including deaths due to CVD, digestive disease, respiratory disease, and infectious disease, showed stronger associations with diabetes among younger than among elderly adults. Moreover, the association of diabetes with risk of death due to diabetes itself was much stronger among those with a BMI less than 18.5 (HR, 95.4; 95% CI, 38.0-239.8) than among those with a BMI of 25.0 or greater (HR, 13.2; 95% CI, 10.7-16.4) (*P*for interaction \< .001).

###### Cause-Specific Mortality Associated With Diabetes Stratified by Individual Characteristics in Asian Populations: Death from Cardiometabolic Diseases

  Characteristic                                                     Adjusted HR (95% CI)[^a^](#zoi190121t4n1){ref-type="table-fn"}                                                            
  ------------------------------------------------------------------ ---------------------------------------------------------------- ------------------ ------------------ ------------------ -------------------
  All patients                                                       2.00 (1.76-2.29)                                                 2.57 (2.19-3.02)   2.15 (1.85-2.51)   1.38 (1.17-1.62)   22.8 (18.5-28.1)
  Sex                                                                                                                                                                                          
  Men                                                                1.82 (1.58-2.09)                                                 2.22 (1.86-2.64)   1.74 (1.49-2.04)   1.35 (1.12-1.62)   23.0 (17.6-30.0)
  Women                                                              2.30 (1.96-2.71)                                                 3.25 (2.64-4.00)   2.95 (2.29-3.78)   1.41 (1.17-1.68)   20.5 (16.3-25.8)
  *P* value for interaction                                          \<.001                                                           \<.001             .002               .74                .54
  Age at baseline, y                                                                                                                                                                           
  \<50                                                               2.95 (2.21-3.92)                                                 3.36 (2.29-4.94)   5.62 (2.37-13.4)   2.42 (1.67-3.49)   29.0 (18.5-45.5)
  50-59                                                              2.43 (2.00-2.96)                                                 3.04 (2.43-3.80)   3.09 (2.32-4.13)   1.58 (1.24-2.00)   21.3 (16.4-27.7)
  60-69                                                              1.96 (1.70-2.27)                                                 2.64 (2.15-3.23)   2.05 (1.75-2.40)   1.45 (1.20-1.75)   20.3 (15.2-27.1)
  ≥70                                                                1.46 (1.30-1.64)                                                 1.92 (1.60-2.29)   1.66 (1.41-1.95)   0.95 (0.74-1.23)   21.7 (15.6-30.2)
  *P* value for interaction                                          \<.001                                                           \<.001             \<.001             \<.001             .10
  Educational attainment[^b^](#zoi190121t4n2){ref-type="table-fn"}                                                                                                                             
  ≤Primary school                                                    2.01 (1.64-2.45)                                                 2.84 (2.25-3.60)   2.15 (1.74-2.66)   1.24 (1.02-1.51)   19.4 (15.5-24.3)
  Secondary school                                                   2.05 (1.75-2.39)                                                 2.47 (2.01-3.03)   2.69 (1.96-3.69)   1.55 (1.25-1.92)   26.9 (19.3-37.7)
  Trade or technical school                                          2.12 (1.87-2.42)                                                 2.56 (2.03-3.23)   1.91 (1.03-3.53)   2.00 (1.42-2.80)   23.1 (12.6-42.5)
  ≥University graduation                                             2.00 (1.57-2.56)                                                 2.26 (1.51-3.36)   1.76 (1.04-2.99)   2.04 (1.34-3.11)   19.6 (12.2-31.5)
  *P* value for interaction                                          .16                                                              .16                .28                .01                .10
  Body mass index[^c^](#zoi190121t4n3){ref-type="table-fn"}                                                                                                                                    
  \<18.5                                                             1.76 (1.41-2.20)                                                 2.51 (1.65-3.82)   1.45 (0.66-3.17)   1.39 (0.85-2.26)   95.4 (38.0-239.8)
  18.5-22.9                                                          2.09 (1.79-2.44)                                                 2.71 (2.26-3.26)   2.07 (1.73-2.48)   1.59 (1.36-1.86)   33.5 (24.6-45.7)
  23.0-24.9                                                          2.11 (1.84-2.43)                                                 2.65 (2.19-3.21)   2.56 (2.04-3.21)   1.64 (1.26-2.13)   22.1 (18.3-26.7)
  ≥25.0                                                              1.89 (1.61-2.21)                                                 2.47 (2.02-3.01)   2.21 (1.78-2.75)   1.20 (0.86-1.66)   13.2 (10.7-16.4)
  *P* value for interaction                                          .20                                                              .16                .39                .07                \<.001
  Smoking status for men                                                                                                                                                                       
  Never                                                              2.04 (1.67-2.49)                                                 2.69 (2.08-3.46)   1.76 (1.14-2.71)   1.38 (0.94-2.02)   25.8 (18.2-36.4)
  Former                                                             1.67 (1.37-2.05)                                                 1.98 (1.52-2.59)   1.87 (1.45-2.42)   1.69 (1.27-2.23)   23.9 (15.6-36.7)
  Current                                                            1.81 (1.58-2.07)                                                 2.24 (1.89-2.65)   1.81 (1.52-2.16)   1.41 (1.19-1.68)   21.1 (15.5-28.9)
  *P* value for interaction                                          .63                                                              .19                .59                .72                .19
  Smoking status for women                                                                                                                                                                     
  Never                                                              2.35 (1.99-2.78)                                                 3.34 (2.73-4.08)   2.83 (2.21-3.62)   1.42 (1.17-1.73)   20.4 (16.3-25.5)
  Former or current[^d^](#zoi190121t4n4){ref-type="table-fn"}        1.97 (1.55-2.51)                                                 2.91 (2.06-4.12)   3.12 (1.83-5.32)   1.48 (1.03-2.12)   15.1 (10.0-22.9)
  *P* value for interaction                                          .48                                                              .14                .37                .78                .17

Abbreviation: HR, hazard ratio.

Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

Cohorts (3 Prefecture Aichi Study, 3 Prefecture Miyagi Study, Ibaraki Prefectural Health Study, Japan Public Health Center-Based Prospective Study 2, Korean Multi-center Cancer Cohort Study) without information on education were not included in the analysis.

Calculated as weight in kilograms divided by height in meters squared.

Former and current smokers were collapsed into 1 category to improve the stability of the point estimate.

###### Cause-Specific Mortality Associated With Diabetes Stratified by Individual Characteristics in Asian Populations: Death From Other Major Diseases

  Characteristic                                                     Adjusted HR (95% CI)[^a^](#zoi190121t5n1){ref-type="table-fn"}                                                            
  ------------------------------------------------------------------ ---------------------------------------------------------------- ------------------ ------------------ ------------------ ------------------
  All patients                                                       1.21 (1.13-1.29)                                                 3.08 (2.50-3.78)   1.98 (1.73-2.25)   1.45 (1.29-1.63)   1.96 (1.59-2.41)
  Sex                                                                                                                                                                                          
  Men                                                                1.20 (1.13-1.29)                                                 2.85 (2.23-3.66)   2.02 (1.78-2.30)   1.50 (1.35-1.68)   1.95 (1.50-2.54)
  Women                                                              1.23 (1.12-1.36)                                                 3.44 (2.66-4.45)   1.95 (1.63-2.33)   1.52 (1.25-1.83)   2.09 (1.62-2.70)
  *P* value for interaction                                          .50                                                              .01                .91                .53                .86
  Age at baseline, y                                                                                                                                                                           
  \<50                                                               1.24 (1.10-1.40)                                                 9.65 (5.04-18.5)   2.90 (2.21-3.82)   3.60 (2.36-5.48)   3.66 (2.00-6.67)
  50-59                                                              1.30 (1.16-1.45)                                                 5.09 (3.71-6.97)   2.53 (1.94-3.30)   2.00 (1.70-2.36)   2.68 (1.81-3.95)
  60-69                                                              1.18 (1.08-1.30)                                                 2.85 (2.03-4.00)   1.85 (1.56-2.19)   1.50 (1.27-1.76)   1.88 (1.43-2.47)
  ≥70                                                                1.18 (1.07-1.29)                                                 2.10 (1.64-2.69)   1.52 (1.18-1.97)   1.18 (1.02-1.36)   2.32 (1.64-3.28)
  *P* value for interaction                                          .11                                                              .66                \<.001             \<.001             .04
  Educational attainment[^b^](#zoi190121t5n2){ref-type="table-fn"}                                                                                                                             
  ≤Primary school                                                    1.20 (1.08-1.33)                                                 3.44 (2.51-4.72)   1.83 (1.47-2.29)   1.41 (1.19-1.68)   2.20 (1.72-2.81)
  Secondary school                                                   1.28 (1.16-1.41)                                                 3.57 (2.53-5.03)   2.40 (1.89-3.06)   1.75 (1.44-2.12)   2.29 (1.47-3.58)
  Trade or technical school                                          1.27 (1.10-1.46)                                                 3.19 (1.83-5.58)   2.97 (1.91-4.62)   1.69 (1.10-2.61)   2.14 (1.26-3.63)
  ≥University graduation                                             1.08 (0.91-1.28)                                                 2.45 (0.87-6.91)   2.76 (1.70-4.49)   1.66 (0.96-2.87)   1.91 (0.67-5.46)
  *P* value for interaction                                          .88                                                              .81                .02                .47                .84
  Body mass index[^c^](#zoi190121t5n3){ref-type="table-fn"}                                                                                                                                    
  \<18.5                                                             1.36 (1.14-1.62)                                                 4.29 (2.68-6.86)   2.80 (1.71-4.60)   1.24 (0.95-1.60)   2.22 (0.98-5.03)
  18.5-22.9                                                          1.25 (1.15-1.36)                                                 3.59 (2.66-4.86)   2.07 (1.59-2.68)   1.48 (1.27-1.73)   2.07 (1.54-2.78)
  23.0-24.9                                                          1.20 (1.09-1.33)                                                 2.91 (2.33-3.63)   2.26 (1.83-2.78)   1.66 (1.45-1.89)   2.42 (1.76-3.33)
  ≥25.0                                                              1.23 (1.10-1.38)                                                 3.09 (2.26-4.24)   2.04 (1.65-2.51)   1.64 (1.34-2.00)   2.20 (1.61-3.01)
  *P* value for interaction                                          .95                                                              .09                .37                .007               .49
  Smoking status for men                                                                                                                                                                       
  Never                                                              1.18 (1.00-1.40)                                                 3.48 (2.51-4.83)   2.31 (1.68-3.19)   1.71 (1.40-2.10)   2.55 (1.58-4.12)
  Former                                                             1.25 (1.13-1.38)                                                 2.32 (1.64-3.28)   1.85 (1.33-2.58)   1.62 (1.42-1.85)   2.33 (1.61-3.35)
  Current                                                            1.19 (1.09-1.29)                                                 2.90 (2.05-4.11)   2.45 (2.01-2.98)   1.47 (1.26-1.72)   2.02 (1.53-2.66)
  *P* value for interaction                                          .39                                                              .42                .18                .09                .55
  Smoking status for women                                                                                                                                                                     
  Never                                                              1.27 (1.16-1.40)                                                 3.46 (2.62-4.59)   1.84 (1.53-2.22)   1.59 (1.30-1.95)   2.17 (1.63-2.89)
  Former or current[^d^](#zoi190121t5n4){ref-type="table-fn"}        1.07 (0.89-1.28)                                                 3.65 (2.31-5.77)   2.82 (1.81-4.41)   1.47 (1.03-2.11)   2.45 (1.09-5.50)
  *P* value for interaction                                          .07                                                              .19                .03                .23                .54

Abbreviation: HR, hazard ratio.

Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

Cohorts (3 Prefecture Aichi Study, 3 Prefecture Miyagi Study, Ibaraki Prefectural Health Study, Japan Public Health Center-Based Prospective Study2, Korean Multi-center Cancer Cohort Study) without information on education were not included in the analysis.

Calculated as weight in kilograms divided by height in meters squared.

Former and current smokers were collapsed into 1 category to improve the stability of the point estimate.

Sensitivity analyses showed that (1) the association between diabetes and mortality did not change when we excluded the participants who had a history of CVD or cancer (eTable 3 in the [Supplement](#note-ZOI190121-1-s){ref-type="supplementary-material"}) and (2) our overall results were not driven by the results from any single cohort or country (eTable 4 in the [Supplement](#note-ZOI190121-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI190121}
==========

This pooled analysis of more than 1 million individuals from 22 Asian cohort studies showed that diabetes is associated with substantially increased risk of death from several diseases, particularly diabetes itself, renal disease, coronary heart disease, and ischemic stroke. Moreover, the magnitude of the associations varied by sex, age, BMI, and smoking status. Women and middle-aged adults showed higher diabetes-related risk of death from all causes, total CVD, coronary heart disease, ischemic stroke, and renal disease than men and older adults. Among women, the risk for all-cause mortality associated with diabetes appeared stronger among those who had never smoked than among current or former smokers. The relative risk of death due to diabetes itself was much stronger among individuals who were underweight than among those who were overweight or obese.

Previous studies^[@zoi190121r18],[@zoi190121r19],[@zoi190121r20],[@zoi190121r21],[@zoi190121r22],[@zoi190121r23],[@zoi190121r24]^ have reported that diabetes leads to an approximate 2-fold risk for all-cause mortality, but the magnitude of the association seems to vary by study. Generally, studies conducted in Western populations^[@zoi190121r20],[@zoi190121r21],[@zoi190121r23]^ reported HRs of 1.15 to 1.90 for all-cause mortality associated with diabetes. Meanwhile, studies conducted in developing countries reported greater HRs, such as 2.00 in mainland China (1.83 in urban areas and 2.17 in rural areas)^[@zoi190121r18]^ and 1.9 to 5.4 in Mexico.^[@zoi190121r19]^ A recent meta-analysis^[@zoi190121r24]^ including 709 503 participants from Western populations and 271 290 Asian individuals (mostly from South Korean) reported an HR for all-cause mortality of 1.69. Our study includes other Asian populations and has a much larger sample size, enabling us to assess associations of diabetes with a larger number of mortality outcomes and potential modifiers in a broader Asian population. The variation in the magnitude of the diabetes-mortality association may be attributed, in part, to differences in diabetes care across populations. Many Asian patients with diabetes, especially those living in less-developed areas, fail to achieve optimal glycemic control and vascular protection owing to a lack of access to health care, antidiabetic medications, and education on diabetes management.^[@zoi190121r1]^

For cause-specific mortality, diabetes was associated with a high relative risk of death from diabetes itself in Asian populations. The excess risks observed in our study are exceptionally high compared with those observed in the United States and in other countries.^[@zoi190121r19],[@zoi190121r20],[@zoi190121r23]^ Furthermore, Asian diabetic populations were much more likely to die from renal disease, the major complication of diabetes, which is in line with the results from studies conducted in low-income countries.^[@zoi190121r18],[@zoi190121r25]^ Evidence has indicated that Asian individuals are more susceptible to insulin resistance, early-onset type 2 diabetes and diabetes unrelated to obesity, and other metabolic disorders (eg, hypertension, hyperlipidemia, and visceral obesity) than populations with European ancestry.^[@zoi190121r1],[@zoi190121r5]^ It is possible that these Asian-specific diabetes phenotypes are associated with a poor prognosis for diabetes and/or elevated risks of acute and chronic complications such as diabetic ketoacidosis and renal failure. Developing and implementing Asian-specific comprehensive diabetes management programs should help reduce mortality due to diabetes itself and/or its complications.

Consistent with the previous report from the ACC^[@zoi190121r10]^ and other Asian studies,^[@zoi190121r22],[@zoi190121r26]^ we observed that diabetes is associated with an increased risk of cancer mortality. In site-specific analyses, we found a positive association with liver, pancreas, and breast cancer, with an etiologic component that includes insulin resistance and obesity, which is in line with previous studies.^[@zoi190121r21],[@zoi190121r23],[@zoi190121r26],[@zoi190121r27],[@zoi190121r28]^ Other findings for a positive association of diabetes with risk of death due to liver disorder; pancreas, gallbladder, and biliary tract-related disease; infection; and mental disorder are supported by previous studies.^[@zoi190121r18],[@zoi190121r19],[@zoi190121r21],[@zoi190121r22],[@zoi190121r23]^ The pathogenesis of type 2 diabetes involves insulin resistance and impaired insulin secretion by β-cell dysfunction.^[@zoi190121r1],[@zoi190121r29]^ Insulin secretion is modulated by the interplay of the pancreas with other organs and tissues such as liver, brain, digestive tracts, and adipose and muscle tissues.^[@zoi190121r30]^ Our findings indicate an increased risk of death due to diseases of these insulin-related organs and tissues among patients with diabetes, highlighting the multifactorial and complicated effect of diabetes and the need for comprehensive health care strategies aimed at the effective management of diabetes and its complications.

We found that the association between diabetes and mortality in Asia varies by sex, age, and BMI, which is supported by previous findings.^[@zoi190121r19],[@zoi190121r20],[@zoi190121r21],[@zoi190121r22],[@zoi190121r23],[@zoi190121r24],[@zoi190121r31],[@zoi190121r32],[@zoi190121r33]^ A previous study suggested that sex difference in the diabetes-mortality association may be attributed, in part, to sex hormones such as estrogens and androgens.^[@zoi190121r24]^ It is also possible that the higher relative risk among women than among men, especially for CVD and renal disease mortality, may reflect gender inequality in diabetes care. Even in developed Western countries, female patients are less likely than male patients to receive optimal care and adhere to recommended treatment.^[@zoi190121r34]^ Our findings for a stronger association of diabetes with risk of death (both all-cause and cause-specific) in younger populations than in elderly populations are also supported by previous studies.^[@zoi190121r19],[@zoi190121r20],[@zoi190121r24]^ These findings are perhaps not surprising because early-onset type 2 diabetes (ie, onset before middle age) is more closely associated with macrovascular cardiovascular complications than late-onset diabetes.^[@zoi190121r35]^ Of note, given the increasing prevalence of early-onset diabetes in Asia,^[@zoi190121r1],[@zoi190121r3],[@zoi190121r4]^ the burden of premature death associated with diabetes is unfailingly projected to increase in the near future.^[@zoi190121r2]^ In addition, the risk of diabetes mortality is much stronger among underweight individuals in Asian populations. Underweight patients may reflect the severity of diabetes and/or the presence of complications due to the poor management of the disease. The significant differences in the diabetes-mortality associations by individual characteristics highlight the need for further attention to vulnerable groups, such as women and young or underweight patients with diabetes, when implementing diabetes management plans at a population level.

Strengths and Limitations {#H2-4-ZOI190121}
-------------------------

To our knowledge, this is the largest prospective investigation of the impact of diabetes on all-cause and cause-specific mortality among Asian populations. In contrast to previous studies that were limited mostly to Asian individuals from developed countries,^[@zoi190121r22],[@zoi190121r24]^ our study populations were composed of Asian individuals from multiple countries and regions at various levels of economic development. The large sample size and the availability of individual participant data of more than 1 million Asian individuals from 22 prospective cohort studies yields great statistical power to assess potential variations in the diabetes-mortality associations by participants' characteristics.

However, we acknowledge several study limitations. First, data on diabetes diagnosis by their doctors were self-reported at baseline. It is possible that some patients who were not aware of their diabetes diagnosis at baseline or were diagnosed with diabetes during the cohort follow-up have been misclassified into the reference group, which could have attenuated the association. The validity of self-reported data in diabetes classification showed a sensitivity of approximately 62% and a specificity of approximately 99% in several participating cohorts.^[@zoi190121r9],[@zoi190121r10],[@zoi190121r11],[@zoi190121r12],[@zoi190121r13]^ With a relatively low prevalence of diabetes in the Asian population, a low sensitivity has less impact on study results than a low specificity. Second, baseline surveys were conducted at different time periods (1963-2006); thus, our results may potentially be influenced by recent changes in diabetes diagnosis and treatment and lifestyle transitions in some Asian countries. To minimize potential time and period effects, our models were stratified by cohort enrollment year and participants' birth year. Future studies using more recent data on diabetes diagnosis, treatment, and lifestyle factors could further evaluate the association of diabetes with mortality outcomes in Asia. Third, we cannot rule out potential influence of residual confounding on our study results, as data on some potential confounding factors were not collected from some cohort members and, thus, could not be adjusted in our study. Fourth, our participants may not fully represent each country or region. In particular, most participating cohorts came from East Asia; thus, the number of South Asian individuals is relatively small. Also, only individuals who are participants of the ACC cohorts are included in the analyses. However, we found comparable risk estimates and similar patterns of the diabetes-mortality association in each country or region when compared with the previous reports,^[@zoi190121r18],[@zoi190121r36],[@zoi190121r37]^ providing some assurance for the overall external validity of our findings.

Conclusions {#H1-5-ZOI190121}
===========

The diabetes epidemic in Asia is expected to continue to accelerate; thus, many Asian individuals will live with diabetes and its complications. Diabetes substantially increases the risk of premature death from several diseases among Asian populations, and the mortality burden associated with diabetes is particularly evident in women and patients with early-onset disease. Our findings suggest the urgent need for developing diabetes management programs that are tailored to Asian populations and the subsequent strong implementation of these programs in Asia.
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